loader
Please Wait
Applying Filters...
menu
    • menu

    Digital Content for Leuprolide Mesylate

    Client Email Product
    PharmaCompass Sponsored Ads

    Virtual Booth

    Contact Supplier

    Bora Pharmaceuticals- Making success more certain.

    Virtual Booth

    Contact Supplier

    Polfa Tarchomin is a leading Polish pharmaceutical company with 200 year tradition in manufacture and sale of pharmaceutical products.

    Virtual Booth

    Contact Supplier

    PharmaCompass Sponsored Ads

    Virtual Booth

    Contact Supplier

    Axplora- The partner of choice for complex APIs.

    Virtual Booth

    Contact Supplier

    Fareva is a one-stop-shop for API/HPAPI, OSD & Sterile products, is USFDA, EMA and PMDA-inspected and has multiple NDA & ANDA filings.

    Virtual Booth

    Contact Supplier

    Menu

    Leuprolide Mesylate

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    PRICE INFORMATION

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    PATENTS & EXCLUSIVITIES

    PharmaCompass
    $ API Ref.Price (USD/KG) : 482,451Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Foresee Announces FDA Orange Book Listing of New U.S. Patent for CAMCEVI
    Foresee Announces FDA Orange Book Listing of New U.S. Patent for CAMCEVI

    29 Aug 2023

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/foresee-pharmaceuticals-announces-fda-orange-book-listing-of-new-us-patent-for-camcevi-extending-patent-protection-to-2039-301912712.html

    PR NEWSWIRE
    29 Aug 2023
    Share Share
    Foresee Announces Submission of NDA for FDA Approval of LMIS 50 mg
    Foresee Announces Submission of NDA for FDA Approval of LMIS 50 mg

    27 Jul 2020

    // PRNASIA

    https://en.prnasia.com/releases/global/foresee-pharmaceuticals-announces-submission-of-nda-for-fda-approval-of-lmis-50-mg-286512.shtml

    PRNASIA
    27 Jul 2020
    Share Share
    Foresee Pharma announces topline results of FP-001 LMIS in prostate cancer
    Foresee Pharma announces topline results of FP-001 LMIS in prostate cancer

    22 Feb 2019

    // BIOSPECTRUM

    https://www.biospectrumasia.com/news/39/12875/foresee-pharma-announces-topline-results-of-fp-001-lmis-in-prostate-cancer.html

    BIOSPECTRUM
    22 Feb 2019
    Share Share